Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Virtual Conferences
Sixth International Conference on Alzheimer’s Disease and Related Disorders


Conference Index | Round Tables | Selected Abstracts | News Summaries

Commentary: Monkey Brain Injections

by Brian Cummings

July 18, 1998 Bruce Yankner took time out from his talk on Down's syndrome (abstract 7) to discuss his recent injection studies in young versus aged rhesus monkeys, published in the July issue of "Nature Medicine." His key findings were that injections of fibrillar Abeta at a "plaque equivalent dose" resulted in cell loss, the proliferation of microglia and tau hyper-phosphorylation in aged animals, but not young ones. These findings are in contrast to earlier studies by Podlisny and Selkoe (where "adult" but not "aged" monkeys were used).

Yankner showed an interesting example of immunocytochemical staining for Abeta revealing an "injected plaque" near a natural plaque in an aged monkey. The injected Abeta was more lightly stained and diffuse than the natural plaque, and was oblong in shape, as if oriented along the needle tract. Without the natural plaque present for comparison, one would have assumed the artificial plaque was real based on morphology. Yankner used several antibodies to hyper-phosphorylated tau, including Ser-262, PHF-1 and AT8 to demonstrate dystrophic neurites in response to the injection. He indicated that Ser-262 yielded the strongest staining, with PHF-1 next and weak staining by AT8. This reaction was not seen in the brains of young rhesus monkeys. In the brief time allotted, he was unable to show slides of vehicle injections in neither aged monkeys nor Abeta injections in young monkeys for the audience to evaluate. Given Selkoe's observations that the neuropil response to vehicle injections was indistinguishable from Abeta injections and Bishop et al's poster (abstract 535) which shows that there is neuronal damage and loss surrounding saline control injections into rat brain this is an important question. The curious will have to examine Yankner's Nature Medicine paper for the details.

Yankner favors the position that extracellular Abeta is the bad guy compared to intracellular Abeta, pointing out that the intracellular Abeta 'load' is "minuscule" compared to the extracellular 'load'. Thus, the toxic effects of extracellular Abeta are probably more important. He hypothesizes that intracellular Abeta from a cell which lyses could lead to a seeding process which accumulates extracellular Abeta, propagating the problem.




Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad